Demographics and baseline characteristics of patients from the BLISS-SC trial included in the analysis
| Parameter | Total population (n=836) | Placebo plus standard therapy (n=280) | Belimumab 200 mg SC plus standard therapy (n=556) |
| Mean (SD) age, years | 38.6 (12.3) | 39.6 (12.6) | 38.1 (12.1) |
| Age group, years, n (%) | |||
| ≤45 | 596 (71.3) | 193 (68.9) | 403 (72.5) |
| 45–65 | 221 (26.4) | 80 (28.6) | 141 (25.4) |
| 65–75 | 18 (2.2) | 7 (2.5) | 11 (2.0) |
| ≥75 | 1 (0.1) | 0 (0) | 1 (0.2) |
| Sex, n (%) | |||
| Female | 789 (94.4) | 268 (95.7) | 521 (93.7) |
| Race, n (%) | |||
| Black African ancestry | 86 (10.3) | 30 (10.7) | 56 (10.1) |
| White/Caucasian | 502 (60.0) | 166 (59.3) | 336 (60.4) |
| Other | 248 (29.7) | 84 (30.0) | 164 (29.5) |
| Country, n (%) | |||
| USA and Canada | 237 (28.4) | 84 (30.0) | 153 (27.5) |
| South America | 172 (20.6) | 57 (20.4) | 115 (20.7) |
| Asia | 172 (20.6) | 61 (21.8) | 111 (20.0) |
| Eastern Europe | 188 (22.5) | 59 (21.1) | 129 (23.2) |
| Western Europe/Australia/Israel | 67 (8.0) | 19 (6.8) | 48 (8.6) |
| Completers,* n (%) | 677 (81.0) | 214 (76.4) | 463 (83.3) |
| Patient-years contributed, mean (SD) | 0.91 (0.2) | 0.92 (0.2) | 0.89 (0.2) |
*All patients who completed all 52 weeks of the planned double-blind treatment period.
SC, subcutaneous; SD, standard deviation.